2022 World Conference on Lung Cancer (ePosters)-EP10.01-001. Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity

EP10.01-001. Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity

Back to course

Pdf Summary

This study examined the dose response and toxicity in patients with limited brain metastases from lung cancer who were treated with hypofractionated stereotactic radiotherapy (HSRT). The researchers retrospectively analyzed data from 48 lung cancer patients with 77 brain metastases who received HSRT at Hangzhou Cancer Hospital. The patients were followed up with MRI every 3 months after treatment.<br /><br />The results showed that increasing the total dose of HSRT for brain metastases could improve local control. However, it is important to be cautious as there may be side effects associated with higher doses. The median follow-up was 10 months, and the median intracranial progression-free survival (iPFS) was 7.5 months.<br /><br />The study also examined the adverse radiation effects (ARE) of HSRT. Among the 48 patients, 13 experienced ARE, with a rate of 27%. The most common ARE was headache, followed by localized edema, nausea, hearing loss, ataxia, and memory impairment. The majority of AREs occurred within 6 months after HSRT.<br /><br />The research did not find a significant effect of histologic tumor type or systemic therapy on the local control rate. The 1-year local failure (LF) rate for all lesions was 15.6%. Patients with a BED10 (biological effective dose with an alpha/beta of 10Gy) of 48Gy had a higher LF rate compared to those with a BED10 of less than 48Gy.<br /><br />In conclusion, this study suggests that increasing the total dose of HSRT for brain metastases in lung cancer patients may improve local control. However, it is crucial to consider the potential side effects. Further research is needed to determine the optimal dose schedule for HSRT in this patient population.

Asset Subtitle

Kaicheng Pan

Meta Tag

Speaker Kaicheng Pan

Topic Palliative and Supportive Care

Keywords

dose response

toxicity

brain metastases

lung cancer

HSRT

local control

side effects

intracranial progression-free survival

adverse radiation effects

optimal dose schedule